ArticleAIDS research and therapy2026
Seroprevalence and viremia of hepatitis C virus among HIV-infected patients on ART with unsuppressed HIV viral load in Ethiopia.
Article in AIDS research and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) share common transmission routes, resulting in a significant burden of co-infection. This study assessed the seroprevalence and viremia of HCV among people living with HIV (PLWH) on ART with unsuppressed viral load in Ethiopia.
methodsA cross-sectional study was conducted between June 2022 and February 2023 among 900 PLWH with unsuppressed viral loads. Plasma samples were screened for HCV antibodies by ELISA, and positives were confirmed for HCV RNA using the Abbott m2000sp/rt PCR system. Data were analyzed using SPSS V 26, applying chi-square tests and logistic regression to assess associations.
resultsAmong 900 participants, 59.3% were females. Overall HCV seroprevalence was 5.4%, with higher rates among females (5.8%) and those aged 40–49 years. Active HCV viremia was confirmed in 14.3% of ELISA-positive cases (0.8% overall). Non-DTG regimens showed higher HCV co-infection (9.7%) than DTG-based regimens (4.4%, p = 0.062). HCV RNA positivity was more frequent in males and participants with medium HIV viral loads.
conclusionA subset of PLWH with unsuppressed viral load showed evidence of HCV exposure and active infection. The result also indicates the exitance of active co-infection HIV/HCV. The data may also reflect spontaneous clearance of HCV or a high rate of past, resolved infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.